Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validated a rich portfolio of novel, clinically relevant cancer targets to 14 different cancer types that have been carefully selected to enable development of new effective therapeutics with fewer and less severe side effects. All of Agensys' cancer targets must meet the following criteria: (1) a novel molecule and/or a novel utility in cancer; (2) expression in a significant percentage of patients' specimens; (3) limited expression in normal vital tissues; and (4) structural and functional features suitable for therapeutic intervention. The Company is generating fully human antibodies to multiple targets from its portfolio, including those directed to prostate, kidney, bladder, colon, lung, ovary and pancreatic cancers. The Company's portfolio also contains multiple validated targets for small molecule and vaccine products that it intends to develop through partnerships with pharmaceutical and biotechnology companies. Agensys has assembled internal capabilities to both develop and manufacture human MAbs. The scientific team has expertise in therapeutic antibody generation, characterization, and development. The company has signed a five year partnership agreement with Abgenix that provides for the generation of human MAbs to 25 Agensys targets using Abgenix' XenoMouse® technologies. Agensys has equipped a 10,000 sq. ft. antibody manufacturing facility with capacity to produce MAbs for clinical trials, offering several advantages, including better control of product development, greater flexibility, a shortened development time line, and substantially reduced cost. Agensys' strategy is to develop a rich cancer product pipeline through (1) in-house clinical development and commercialization of selected human MAb products, and (2) corporate partnerships for some of its antibody products and its proprietary targets suitable for the development of small molecule drugs and vaccines.